Investment
Dialybrid secured a €15M Series A round and announced first-in-human implant of its Silkothane Arteriovenous Graft for hemodialysis vascular access.
Dialybrid
SEP 2026
Milestone
Genespire and SR-TIGET published durable preclinical efficacy data for a liver-directed gene therapy for methylmalonic acidemia.
Genespire
JUL 2026
Milestone
Tes Pharma received FDA Orphan Drug Designation for TESP-0401 for the prevention of delayed graft function after renal transplantation.
Tes Pharma
JUL 2026
Milestone
EpilepsyGTx appointed Dr Teresa Nunes as Chief Medical Officer.
EpilepsyGTX
JUL 2026
Milestone
Nouscom received U.S. FDA Fast Track Designation for NOUS-209, a novel immunotherapy for the prevention of Lynch Syndrome-associated cancers.
Nouscom
JUN 2026
Milestone
Tes Pharma received HREC approval to initiate a Phase I clinical trial of lead drug TESP-0401 for prevention of DGF following kidney transplantation.
Tes Pharma
JUN 2026
Milestone
AAVantgarde announced completion of recruitment in its STELLA natural history study.
AAVantgarde
APR 2026
Milestone
EpilepsyGTx appointed Professor Dimitri Kullmann as Chief Scientific Officer.
EpilepsyGTX
APR 2026
Milestone
Gesynta Pharma dosed the first patient in its Phase 2 proof-of-concept endometriosis trial (NOVA) of vipoglanstat.
Gesynta Pharma
MAR 2026